Condition: Relapsed/Refractory B Cell-Mediated Autoimmune Diseases · Sponsor: Ruijin Hospital
This Phase 1, open-label study evaluates the safety, tolerability, and preliminary efficacy of RXIM002, a CD19-targeting circular RNA-mediated in-vivo CAR T-cell therapy, in adults with severe, relapsed, or refractory B cell-mediated autoimmune diseases.
This description comes directly from the study's public registry record.
Qiongyi Hu · +86 021-50199835 · huqiongyi131@163.com
Always discuss trial participation with your own doctor first.
| Ruijin Hospital | Shanghai, Huangpu District, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07322718